Diagnosis and management of Crohn's disease

American Family Physician

Volumn 84, Issue 12, 2011, Pages 1365-1375

  Wilkins, Thad ^a   Jarvis, Kathryn ^b   Patel, Jigneshkumar ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b McLeod Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ADALIMUMAB; ALBUMIN; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; C REACTIVE PROTEIN; CALGRANULIN; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; CYANOCOBALAMIN; FOLIC ACID; INFLIXIMAB; LACTOFERRIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; OLSALAZINE; PLACEBO; PREALBUMIN; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALAZOSULFAPYRIDINE; VITAMIN D;

ABDOMINAL PAIN; ABSCESS; AGRANULOCYTOSIS; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; ANUS FISTULA; ARTHRALGIA; ARTICLE; BACTERIAL INFECTION; BEDTIME DOSAGE; BONE MARROW SUPPRESSION; CAPSULE ENDOSCOPY; CELLULITIS; CLINICAL FEATURE; COLON CROHN DISEASE; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; CROHN DISEASE; DEPRESSION; DIAGNOSTIC ACCURACY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG COST; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPNEA; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FECES CULTURE; FLUID RETENTION; FLUSHING; GASTRITIS; HEPATIC ENCEPHALOPATHY; HEPATOSPLENIC T CELL LYMPHOMA; HOSPITALIZATION; HUMAN; HYPERNATREMIA; HYPERPIGMENTATION; HYPERTENSION; HYPOTENSION; IMMUNE DYSREGULATION; IMMUNOMODULATION; INFECTION; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LABORATORY TEST; LATENT TUBERCULOSIS; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; LUPUS LIKE SYNDROME; LYMPHOMA; MAINTENANCE THERAPY; MALE INFERTILITY; MALIGNANT NEOPLASTIC DISEASE; MORNING DOSAGE; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATITIS; PHOTOSENSITIVITY; PHYSICAL EXAMINATION; PNEUMONIA; PRURITUS; REMISSION; RESPIRATORY TRACT INFECTION; SCINTIGRAPHY; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SINUSITIS; SKIN ULCER; STOMATITIS; SYSTEMIC MYCOSIS; T CELL LYMPHOMA; THORAX PAIN; THROMBOCYTOPENIA; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING;

EID: 83455208037     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007; 5(12): 1424-1429.
2. Sandler RS, Loftus EV. Epidemiology of inflammatory bowel disease. In: Sartor RB, Sandborn WJ, Kirsner JB, eds. Kirsner's Inflammatory Bowel Diseases. 6th ed. Edinburgh, United Kingdom: Saunders, 2004: 245-262.
3. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008; 24(2): 319-328.
4. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361(21): 2066-2078.
5. Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Gendre JP. Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study. Gut. 1999; 45(2): 218-222.
6. Yamamoto T, Keighley MR. Smoking and disease recurrence after operation for Crohn's disease. Br J Surg. 2000; 87(4): 398-404.
7. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006; 4(2): 196-202.
8. Stange EF, Travis SP, Vermeire S, et al.; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006; 55(suppl 1): i1-i15.
9. Cummings JR, Keshav S, Travis SP. Medical management of Crohn's disease. BMJ. 2008; 336(7652): 1062-1066.
10. Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med. 2010; 42(2): 97-114.
11. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999; 340(18): 1398-1405.
12. Horsthuis K, Bipat S, Bennink RJ, Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology. 2008; 247(1): 64-79.
13. Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004; 99(11): 2235-2241.
14. Kallel L, Ayadi I, Matri S, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2010; 22(3): 340-345.
15. Sidhu R, Wilson P, Wright A, et al. Faecal lactoferrin-a novel test to differentiate between the irritable and inflamed bowel? Aliment Pharmacol Ther. 2010; 31(12): 1365-1370.
16. Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008; 68(2): 255-266.
17. Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol. 2005; 100(10): 2225-2229.
18. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2007; (1): CD000542.
19. Colombel JF, Lémann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol. 1999; 94(3): 674-678.
20. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology. 2002; 123(1): 33-40.
21. Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008; (3): CD000296.
22. Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008; (2): CD006792.
23. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000; (2): CD000545.
24. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006; 130(3): 935-939.
25. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2005; (1): CD003459.
26. Vandeputte L, D'Haens G, Baert F, Rutgeerts P. Methotrexate in refractory Crohn's disease. Inflamm Bowel Dis. 1999; 5(1): 11-15.
27. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345(15): 1098-1104.
28. Osterman MT, Lichtenstein GR. Current and future anti-TNF therapy for inflammatory bowel disease. Curr Treat Options Gastroenterol. 2007; 10(3): 195-207.
29. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56(9): 1232-1239.
30. Kornbluth A, Marion JF, Salomon P, Janowitz HD. How effective is current medical therapy for severe ulcerative and Crohn's colitis? An analytic review of selected trials. J Clin Gastroenterol. 1995; 20(4): 280-284.
31. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol. 1984; 79(7): 533-540.
32. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000; (2): CD000067.
33. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placeboor the maintenance of remission in Crohn's disease. North American Crohn's's Study Group Investigators. N Engl J Med. 2000; 342(22): 1627-1632.
34. D'Haens G, Baert F, van Assche G, et al.; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371(9613): 660-667.
35. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2003; (4): CD000301.
36. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev. 2005; (1): CD003715.
37. Benchimol EI, Seow CH, Otley AR, Steinhart AH. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009; (1): CD002913.
38. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010; 105(2): 289-297.
39. Andersson P, Olaison G, Hallböök O, Sjödahl R. Segmental resection or subtotal colectomy in Crohn's colitis? Dis Colon Rectum. 2002; 45(1): 47-53.
40. Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003; 125(2): 320-327.